| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c6585b2f1254cf3d6051c4118a28f8b0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497 |
| filingDate |
2020-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75f2f94fc050e866704fcf5610d160a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f5b3ebc81172718f4b04a425a0ef054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1f8dfba3b059e48caed4949be6504fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18ce16d85377fad288273b03bf7877cb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b30ca67b797045fef0d164348cba841 |
| publicationDate |
2021-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-3153639-A1 |
| titleOfInvention |
Pediatric trazodone compositions and method of treatment thereof |
| abstract |
The invention relates to trazodone for use in the treatment of insomnia in the pediatric population, wherein said pediatric population is affected by an Intellectual Disability or a Neurodevelopmental Disorder. The invention also relates to pediatric formulations at a trazodone concentration comprised of from 0.1 to 4% and pediatrically suitable excipients. |
| priorityDate |
2019-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |